The present invention encompasses a method of evaluating pharmaceutical compositions of meloxicam whereby one can correlate in vitro properties to in vivo properties, and pharmaceutical compositions developed using the method.

Methods and devices for protein assays based on Edman degradation in microfluidic channels are disclosed herein. As disclosed, the cleaved amino acid residues may be immobilized in an array format and identified by detectable labels, such as antibodies, which specifically bind given amino acid residues. Alternatively, the antibodies are immobilized in an array format and the cleaved amino acids are labeled identified by being bound by the antibodies in the array.

A novel method of molecular imprinting is described. Using a modified soft lithography technique, a molecularly-imprinted chemical detection device comprising at least one molecularly-imprinted polymer capable of detecting at least one chemical target is produced. The device can be used in the field for in situ detection and quantification of chemical targets using standard surface analytical techniques.

An immunochemical label comprising finely particulate carbon black on which is adsorptively immobilized a component which terminates distally from a point of adsorption with an immunologically active ligand or ligand binding molecule wherein said component comprises said immunological ligand or ligand binding molecules covalently linked through a linking reagent, and said linking reagent is adsorbed on the surface of said carbon black.

A lateral flow device is disclosed. The lateral flow device includes a substrate having a flow path and a detection zone disposed along the flow path. The detection zone includes an immobilized target-binding moiety directed against a target of a Raman-active complex. A portion of the detection zone has a dimension that is less than another dimension of the lateral flow device upflow from the detection zone or a first region of the detection zone has a chemical difference from a second region of...

The present invention describes peptides and recombinant proteins containing Hepatitis C virus core protein sequence in which one or more of the amino acids have been modified or deleted to remove the ability of these proteins to bind to specific anti-HCV murine monoclonal antibodies. The deletions and modifications are designed as to maintain the ability of this protein to be used in immunoassays used for the detection of anti-HCV antibodies in individuals infected with HCV.

A method for assessing muscle damage in a biological sample obtained from a subject is disclosed. The method involves obtaining a biological sample from a subject being assessed for muscle damage, and evaluating the sample for the presence or absence of a myofilament protein modification product. The method can also be used to assess the extent and/or type of muscle damage in a subject by studying the profile of myofilament protein modification products detected in the sample taken from the subj...

In a method for examination of the surface of an object for a topographic and/or a chemical property, the object-surface is impinged with surface-structure selective biocomponents for examination of a topographic property and/or with chemoselective biocomponents for the examination of a chemical property, together with a nutrient medium and/or an osmotic protective medium for the biocomponents. The biocomponents contained in the nutrient medium and/or the osmotic protective medium are in contact...

Described herein is an ELISA based assay for the detection of HCV infection. This new assay can detect HCV infection earlier than the currently used assays for the screening of blood for HCV infection by using a combination of HCV antigens and anti-core antibodies to capture HCV.

Combinatorial libraries are disclosed which are represented by Formula I: ##STR1## wherein: ##STR2## is a solid support; T'--L-- is an identifier residue; and --L'--II' is a ligand/linker residue. These libraries contain dihydrobenzopyrans of the formula ##STR3## which interact (i.e., as agonists or antagonists) with .alpha. adrenergic receptors, dopamine receptors, .sigma.-opiate receptors, and K.sup.+ channels and are inhibitors of carbonic anhydrase isozymes. They are useful in the treatment ...